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Background & Objectives:
Copy number variants (CNVs) represent a large proportion of genetic variation in the human
genome and contribute to a number of disorders. Traditional microarray platforms designed to
detect large CNVs (>25 kb) often have suboptimal probe coverage within exonic regions of
medically relevant genes, which hinders detection of smaller events. In 2016, our laboratory
clinically validated exon deletion/duplication microarray (EDDM) for detection of smaller CNVs to
complement non-diagnostic results from NGS-based sequencing and traditional microarray. EDDM
platforms are designed with high probe coverage within the exons of genes and are more sensitive
in detecting small CNVs than traditional microarray. Here, we evaluate the clinical utility of EDDM
as an adjunct to NGS-based analysis and traditional microarray.

Methods/Design:
Between May 2016-November 2018, 416 consecutive patients were referred to our laboratory for
EDDM testing either as a primary test based on clinical indication or as a follow-up after nondiagnostic NGS testing. The majority of these cases were also previously analyzed by traditional
microarray with non-diagnostic results. DNA extracted from blood was run using the CytoSure OGT
1x1M Medical Exome or CytoScan Xon array platforms.

Results:
Of the 416 cases, 106 (25%) were ordered as single or multi-gene panel and 310 (75%) as exomewide deletion/duplication analysis. In total, 15 diagnostic CNVs were found (13 pathogenic and 2
likely pathogenic; 12 deletions and 3 duplications), which accounts for 3.6% of all cases. The
remaining cases, 96.4% (401/416) were non-diagnostic. Of these, 6 patients were found to be
carriers of pathogenic autosomal or X-linked recessive CNVs, and 66 (17%) had reportable variants
of uncertain significance (VUS) with 16 novel or rare CNVs not previously identified by traditional
microarray.
All of the 15 diagnostic CNVs detected by EDDM [7 small (500bp-19kb) and 8 large (41kb-12.3Mb)]
were associated with dominant conditions. Of these, 2 had CNVs in clinically suspected genes
identified by the EDDM platform alone, 2 had CNVs in the ordered genes after negative NGS
analysis of those genes and 4 had CNVs identified by exome-wide EDDM analysis after negative
whole-exome sequencing (WES) results. An additional 4 cases had deletions previously detected by
outside laboratories using NGS, however, EDDM was performed to clarify the breakpoints of those
deletions. Finally, 3 cases had large (>2 Mb) CNVs which included a 22q11.21 duplication, a
13q12.3q14.11 mosaic deletion and a complex 1p36 duplication.
Conclusions:
Overall, the use of the EDDM platform in our laboratory yielded a diagnostic rate of ~3.6%. All of
the diagnostic cases were associated with dominant conditions, although, we also identified 6 cases
with CNVs indicating carrier status for autosomal and X-linked recessive diseases that appeared to
be incidental. Exon-level resolution of the EDDM platform provides higher sensitivity as
exemplified by several cases in which clinically relevant deletions were not detected by traditional
microarray. Our experience shows that targeted EDDM analysis for specific dominant disease has
high clinical utility; however overall it significantly increases costs. EDDM may be most useful in
cases where there is a strong suspicion for a specific disorder.

